Trial · NCT02055781

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

NCT02055781, Phase 3, Terminated, CTI BioPharma; results first posted 2021-11-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia. Trials, record NCT02055781. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02055781

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT number: NCT02055781
Status: Terminated
Phases: Phase 3
Enrollment: 311 participants, actual
Lead sponsor: CTI BioPharma
Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Best Available Therapy
First posted: 2014-02-05
Last updated: 2021-11-18
Results first posted: 2021-11-18

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Spleen Volume Reduction	Baseline to Week 24	Proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT).
Primary	Total Symptom Score (TSS) Reduction	Baseline to Week 24	Proportion of patients achieving a ≥ 50% reduction in the total symptom score from baseline to Week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Spleen Volume Reduction	Baseline to Week 24		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Total Symptom Score (TSS) Reduction	Baseline to Week 24		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Spleen Volume Reduction	Pacritinib, Once Daily	11	Participants
Spleen Volume Reduction	Pacritinib, Twice Daily	16	Participants
Spleen Volume Reduction	Best Available Therapy	2	Participants
Total Symptom Score (TSS) Reduction	Pacritinib, Once Daily	13	Participants
Total Symptom Score (TSS) Reduction	Pacritinib, Twice Daily	24	Participants
Total Symptom Score (TSS) Reduction	Best Available Therapy	10	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pacritinib, QD	104
Overall Study	STARTED	Pacritinib, BID	107
Overall Study	STARTED	Best Available Therapy	100
Overall Study	COMPLETED	Pacritinib, QD	62
Overall Study	COMPLETED	Pacritinib, BID	79
Overall Study	COMPLETED	Best Available Therapy	63
Overall Study	NOT COMPLETED	Pacritinib, QD	42
Overall Study	NOT COMPLETED	Pacritinib, BID	28
Overall Study	NOT COMPLETED	Best Available Therapy	37

Source ClinicalTrials.gov

Adverse events573

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Contusion	Injury, poisoning and procedural complications	Pacritinib, Once Daily	7	104	7
other	Contusion	Injury, poisoning and procedural complications	Pacritinib, Twice Daily	10	106	10
other	Contusion	Injury, poisoning and procedural complications	Best Available Therapy	8	98	8
other	Fall	Injury, poisoning and procedural complications	Pacritinib, Once Daily	7	104	7
other	Fall	Injury, poisoning and procedural complications	Pacritinib, Twice Daily	5	106	5
other	Fall	Injury, poisoning and procedural complications	Best Available Therapy	3	98	3
other	Weight decreased	Investigations	Pacritinib, Once Daily	4	104	4
other	Weight decreased	Investigations	Pacritinib, Twice Daily	7	106	7
other	Weight decreased	Investigations	Best Available Therapy	3	98	3
other	Epistaxis	Respiratory, thoracic and mediastinal disorders	Pacritinib, Once Daily	11	104	11

1 to 10 of 573Source ClinicalTrials.gov

See all 573 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pacritinib, Once Daily	22	104
Total, all-cause mortality	Pacritinib, Twice Daily	20	107
Total, all-cause mortality	Best Available Therapy	20	100
Total, other adverse events	Pacritinib, Once Daily	104	104
Total, other adverse events	Pacritinib, Twice Daily	100	106
Total, other adverse events	Best Available Therapy	87	98
Total, serious adverse events	Pacritinib, Once Daily	48	104
Total, serious adverse events	Pacritinib, Twice Daily	50	106
Total, serious adverse events	Best Available Therapy	30	98

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29522138	BACKGROUND	PubMed
33275766	DERIVED	PubMed
34551507	DERIVED	PubMed
39400386	DERIVED	PubMed
42316774	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02055781

GET https://conductscience.org/api/trials/v1/NCT02055781/events?page=2

API reference For AI assistants